Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy

15 Feb 2008

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 18276770
DOI: 10.2353/jmoldx.2008.070128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor TherapyPMID 18276770Read ↗

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.Semantic proximity Read ↗

[Clinical significance of analysis of BCR- ABL kinase domain mutation in chronic myeloid leukemia patients].Semantic proximity Read ↗

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcomeSemantic proximity Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patientsSemantic proximity Read ↗

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studySemantic proximity Read ↗

Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?Semantic proximity Read ↗

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.Semantic proximity Read ↗

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaSemantic proximity Read ↗

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Semantic proximity Read ↗

BCR-ABL Mutations in Chronic Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.